Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

[News]

The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

More... (http://www.news-medical.net/news/20120721/Novartis-receives-FDA-approval-for-Afinitor-to-treat-HER2-negative-breast-cancer.aspx)